EU device directive recast could save money for innovative businesses, says Minor
This article was originally published in Clinica
The European Commission hopes that the recast of the medical device directives, the first draft of which it plans to propose in April next year, will enable innovative medtech businesses to save money on administrative costs and plough these savings back into research and development to bring further innovation.
You may also be interested in...
Only just over a month ago there were fears that the implementation of the EU Medical Device Regulation was going to be hampered by a lack of expert panel applicants. Now it seems there is no shortage. The news raises lots of questions about when and how the structure will now work.
The European Commission’s announcement of a lengthy delay to the Eudamed database launch date has generally been met with dismay, with member states challenging the decision. Now there is news of a concession.
Not only is the EU due to be endorsing key guidance documents this week, but recent headline topics, including appointing expert panels and the delay in setting up the Eudamed database feature on end of week Medical Devices Coordination Group meeting agenda.